Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease - Palisade Bio

Skip to main content

About Us
Overview

Leadership Team

Board of Directors

Clinical Advisory Board
Our Approach
PDE4 Prodrug

Publications
Pipeline
Overview

PALI-2108
Investors & News
Overview

Press Releases

Events & Presentations

Analyst Coverage

SEC Filings

Corporate Governance

Stock Information

FAQs

Email Alerts
Contact

QUICK LINKS

Home
About
Our Approach
Pipeline
Contact

Investors & News

Overview
Press Releases
Events & Presentations
Analyst Coverage
SEC Filings
Corporate Governance

Stock Information
FAQs
Email Alerts

About Us

Overview
Leadership Team
Board of Directors
Clinical Advisory Board

© 2026 Palisade Bio. All rights reserved.

Privacy Policy | Terms of Use | Accessibility